3 most recent filings and news items mentioning CTXR. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/CTXR/news?limit=20"
Pull CTXR filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayContext Therapeutics released a corporate presentation outlining its strategy for advancing T cell engager therapies targeting solid tumors. The presentation includes forward-looking statements regarding clinical development timelines, potential market opportunities, and funding
View filing at SEC.gov →Citius Oncology presented Phase 1 data at ASCO showing LYMPHIR combined with pembrolizumab achieved 24% overall response rate and 48% clinical benefit rate in heavily pre-treated gynecologic cancer patients, including 33% response rate in endometrial cancer. The encouraging effic
View filing at SEC.gov →Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. The positive clinical signals
View filing at SEC.gov →